The SEC case. Most likely another 10 million out the door for ACT2.
This caused the small pop:
Advanced Cell Technology, Inc. (OTCQB: ACTC). The stock has extended its gains after the company announced that it achieved clinical milestone. The company said that investigators for its Phase 1/2 clinical trials for Stargardts macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) observed evidence of engraftment of the transplanted hESC-derived retinal pigment cells and visual acuity in patients treated over 18 months.